{"brief_title": "A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.", "brief_summary": "To compare the antiviral effect of stavudine ( d4T ) versus placebo in patients with evidence of recent HIV infection. Also, to compare the immunologic effects and effects on quality of life of d4T in these patients.", "detailed_description": "Patients receive d4T or placebo every 12 hours for 4 weeks, after which dose decreases (or placebo) every 12 hours. Treatment continues for at least 48 weeks.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Stavudine", "criteria": "Inclusion Criteria Patients must have: - Recent HIV infection. - No prior antiretroviral therapy. - No acute opportunistic infection at study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Intractable diarrhea. - Bilateral peripheral neuropathy. - Any other condition that would preclude study therapy. Concurrent Medication: Excluded: - Myelosuppressive, neurotoxic, or hepatotoxic drugs. Patients with the following prior condition are excluded: History of bilateral peripheral neuropathy. Prior Medication: Excluded: - Prior antiretroviral therapy. - Myelosuppressive, neurotoxic, or cytotoxic agents within 3 months prior to study entry.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002349.xml"}